Stage 4 melanoma is not considered curable in the traditional sense, but a meaningful percentage of patients now achieve long-term remission that looks and functions like a cure. The 5-year survival rate for metastatic melanoma is 34 to 35%, a dramatic improvement from the era before modern immunotherapy, when fewer than 10% of patients survived five years. Some patients live a decade or longer with no detectable cancer after treatment.
This shift happened almost entirely in the last 15 years. Before 2011, there were essentially no treatments that reliably extended life for people with stage 4 melanoma. Today, a combination of immunotherapy, targeted therapy, and newer cell-based treatments has turned what was once a rapid death sentence into a disease where long-term survival is a realistic possibility for many patients.
How Immunotherapy Changed the Outlook
The biggest leap in stage 4 melanoma survival came from checkpoint inhibitors, drugs that remove the brakes cancer puts on the immune system. The landmark CheckMate 067 trial tested a combination of two checkpoint inhibitors and recently reported 10-year follow-up data. Patients who received the combination had a median overall survival of nearly 72 months (about 6 years), and 37% were still alive at the end of the study with more than 10 years of follow-up. For context, patients on the older single-agent immunotherapy in that same trial had a median survival of just 20 months.
What’s particularly striking is the shape of the survival curve. After about three to four years, the line flattens. Patients who are still alive at that point tend to stay alive, suggesting their immune systems have gained lasting control over the cancer. This plateau is the closest thing to a “cure” that oncologists see in stage 4 melanoma, and it applies to roughly one in three patients who receive combination immunotherapy.
Among patients who achieve a complete response (no detectable cancer on scans), the outlook is even better. Data on 78 patients who stopped immunotherapy after a complete response found that only about 17% experienced a recurrence. The rest remained cancer-free, meaning the vast majority of complete responders can discontinue treatment and stay in remission.
Targeted Therapy for BRAF-Positive Melanoma
About half of all melanomas carry a specific gene mutation called BRAF. For these patients, targeted drugs that block the signals driving cancer growth offer another treatment path. Five-year follow-up from the BRIM7 trial showed that 39% of patients who hadn’t received prior targeted treatment were still alive at five years, with survival plateauing at the four- and five-year marks. About 20% of those patients had no cancer progression at five years.
Targeted therapy tends to work faster than immunotherapy. Tumors often shrink within weeks. The trade-off is that resistance develops more frequently, which is why many oncologists now use targeted therapy and immunotherapy in sequence or combination. Patients whose cancer progresses on targeted therapy alone have a five-year survival rate closer to 14%.
What Affects Your Chances
Not all stage 4 melanoma carries the same prognosis. Where the cancer has spread matters enormously. Melanoma that has reached the skin or distant lymph nodes (classified as M1a) carries a better outlook than cancer in the lungs, which in turn is more favorable than spread to the liver or brain (M1c). Liver metastases are particularly aggressive and harder to control.
One of the strongest predictors is a blood marker called LDH, an enzyme that rises when there’s significant tissue damage or high tumor burden. Patients with elevated LDH have dramatically shorter progression-free survival compared to those with normal levels. In one study, progression-free survival dropped from an extended period (median not reached) in patients with normal LDH to just 5 months in those with elevated levels. Among patients whose disease progressed on treatment, nearly 80% had elevated LDH. High LDH also correlates with having three or more metastatic sites and liver involvement, all of which signal more advanced disease.
The number of metastatic sites, overall health, and whether the tumor carries the BRAF mutation (which opens up additional treatment options) all influence outcomes. Younger patients and those with fewer symptoms at diagnosis also tend to fare better.
Options When Standard Treatments Stop Working
For patients whose melanoma progresses through both immunotherapy and targeted therapy, a newer approach called TIL therapy offers a real option. This treatment extracts immune cells directly from a patient’s tumor, grows billions of them in a lab, and infuses them back into the body. In a pooled analysis of patients with heavily pretreated advanced melanoma, TIL therapy produced an objective response rate of 31%, including complete responses in some patients. Notably, the median duration of response hadn’t been reached after more than two years of follow-up, and over 40% of responses lasted 18 months or longer. This is significant because these were patients who had already failed other treatments.
What Long-Term Remission Looks Like
Living with stage 4 melanoma in remission involves regular monitoring, typically with imaging scans and blood work every few months in the early years, gradually spacing out over time. The anxiety around scan days is real and common. Many patients describe a shift in identity, moving from “actively fighting cancer” to “living with uncertainty.”
For patients on immunotherapy, treatment duration varies. Some stay on it for two years if responding well, then stop. Others continue longer. Side effects from checkpoint inhibitors can include fatigue, skin rashes, and inflammation in various organs. These side effects sometimes persist even after treatment ends, because the immune system has been permanently recalibrated. Thyroid problems, joint pain, and skin changes are among the most common lasting effects.
The practical reality is that stage 4 melanoma today exists on a spectrum. Some patients achieve a complete response within months and remain cancer-free for a decade or more. Others cycle through multiple lines of treatment, each buying months to years. The 34% five-year survival rate is an average that includes both groups, and it continues to climb as newer treatments reach patients earlier and in smarter combinations.